Inicio>>Signaling Pathways>> Neuroscience>> 5-HT Receptor>>Ritanserin

Ritanserin (Synonyms: R-55-667)

Catalog No.GC13883

La ritanserina (R 55667) es un antagonista del receptor 5-HT2 muy potente, relativamente selectivo, activo por vÍa oral y de acciÓn prolongada, con una IC50 de 0,9 nM, menos activo en los receptores de histamina H1, dopamina D2, adrenérgicos α1 y adrenérgicos α2 .

Products are for research use only. Not for human use. We do not sell to patients.

Ritanserin Chemical Structure

Cas No.: 87051-43-2

Tamaño Precio Disponibilidad Cantidad
5mg
48,00 $
Disponible
10mg
83,00 $
Disponible
25mg
182,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Ritanserin (R 55667) is a highly potent, relatively selective, orally active, long acting antagonist of 5-HT2 receptor, with an IC50 of 0.9 nM, less active on Histamine H1, Dopamine D2, Adrenergic α1, Adrenergic α2 receptors[1].

Ritanserin (R 55667) is a highly potent, relatively selective, long acting antagonist of 5-HT2 receptor, with an IC50 of 0.9 nM, less active on Histamine-H1 (IC50, 35 nM), Dopamine-D2 (IC50, 70 nM), Adrenergic-α1 (IC50, 97 nM), Adrenergic-α2 receptor (IC50, 150 nM)[1].

References:
[1]. Leysen JE, et al. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. Mol Pharmacol. 1985 Jun;27(6):600-11.

Reseñas

Review for Ritanserin

Average Rating: 5 ★★★★★ (Based on Reviews and 13 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ritanserin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.